Abstract
Apremilast (AP) is a new phosphodiesterase 4 inhibitor for the treatment of psoriasis and psoriatic arthritis (PsA). Treatment with AP reduces the level of proinflammatory cytokines and the activity of inflammatory changes. The positive impact of AP treatment on the course of psoriasis has been proven in a number of clinical trials, for example ESTEEM 1 (Efficacy and Safety Trial Evaluating the Effects of apreMilast in psoriasis), in which the treatment with AP has led to a decrease in PASI scores in patients with moderate and severe psoriasis en plaque: after 16 weeks, a 75% PASI improvement was significantly more common in patients taking AP 30 mg twice daily (33%) than in those who used placebo (PL) (5%) (p = 0.0001). In the PALACE 1 trial, the PsA patients were given AP at a dose of 20 or 10 mg twice daily. At 16 weeks, the patients who used AP at doses 20 and 30 mg twice daily, more frequently showed a 20% improvement according to the American College of Rheumatology (ACR) response criteria (ACR20) than those who received PL (in 30.4, 38.1, and 19% of cases; p = 0.0166 and p = 0.0001, respectively). Following 52 weeks of AP treatment, ACR20 was achieved by 63.0% of the patients who took the drug at 20 mg twice daily, and by 54.6% of those who used 30 mg twice daily. The PALACE 1, PALACE 2, and PALACE 3 trials demonstrated that the most common adverse events (AE) were diarrhea, nausea, headache, upper respiratory tract infections, and nasopharyngitis. Most AE were mild and moderate; and the rate of therapy discontinuation due to AE was low. These PALACE trials covering 1493 patients have provided evidence for the efficacy and safety of AP in treating moderate PsA activity.
Highlights
Корсакова Ю.Л. – старший научный сотрудник лаборатории клинических исследований и международных связей ФГБНУ НИИР им
Положительное влияние терапии АП на течение псориаза было доказано в ряде клинических исследований, например ESTEEM 1 (Efficacy and Safety Trial Evaluating the Effects of apreMilast in psoriasis), в котором лечение АП привело к снижению индекса PASI у больных среднетяжелым и тяжелым бляшечным псориазом: через 16 нед 75% улучшение PASI значительно чаще наблюдалось у больных, принимавших АП в дозе 30 мг дважды в день (33%), чем при использовании плацебо (ПЛ) – 5% (p=0,0001)
The positive impact of AP treatment on the course of psoriasis has been proven in a number of clinical trials, for example ESTEEM 1 (Efficacy and Safety Trial Evaluating the Effects of apreMilast in psoriasis), in which the treatment with AP has led to a decrease in PASI scores in patients with moderate and severe psoriasis en plaque: after 16 weeks, a 75% PASI improvement was significantly more common in patients taking AP 30 mg twice daily (33%) than in those who used placebo (PL) (5%) (p = 0.0001)
Summary
Корсакова Ю.Л. – старший научный сотрудник лаборатории клинических исследований и международных связей ФГБНУ НИИР им. Положительное влияние терапии АП на течение псориаза было доказано в ряде клинических исследований, например ESTEEM 1 (Efficacy and Safety Trial Evaluating the Effects of apreMilast in psoriasis), в котором лечение АП привело к снижению индекса PASI у больных среднетяжелым и тяжелым бляшечным псориазом: через 16 нед 75% улучшение PASI значительно чаще наблюдалось у больных, принимавших АП в дозе 30 мг дважды в день (33%), чем при использовании плацебо (ПЛ) – 5% (p=0,0001).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.